Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.
Humans
United States
/ epidemiology
Adverse Drug Reaction Reporting Systems
/ statistics & numerical data
Anti-Obesity Agents
/ adverse effects
United States Food and Drug Administration
Male
Female
Adult
Pharmacovigilance
Middle Aged
Databases, Factual
Aged
Young Adult
Digestive System Diseases
/ chemically induced
Obesity
/ epidemiology
Liraglutide
/ therapeutic use
Adolescent
Anti-obesity medications
Digestive adverse events
Disproportionality analysis
FDA adverse event reporting system database
Obesity
Pharmacovigilance
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
22
04
2024
accepted:
06
09
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
12
9
2024
Statut:
epublish
Résumé
Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of these medications. However, most current studies are limited to the association of one class of drugs with specific digestive disorders, and there is no cascading analysis of AOMs in the digestive system. This study aims to use data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) for a stratified analysis of the reported associations between AOMs and dsAEs. We analyzed adverse event reports submitted to FAERS between January 2015 and December 2023 related to obesity treatment. It is important to note that FAERS data cannot establish causality or incidence rates. Pharmacovigilance (PV) signals were detected by disproportionate analyses through proportionate reporting ratio (PRR), reporting odds ratios (ROR), and information components (IC) to detect dsAEs associated with AOMs. Reporting rates, severity, and response outcomes of digestive adverse events were compared across AOMs by multivariate logistic regression analysis. Among 34,396 adverse events (AEs) related to obesity treatment, 8844 dsAEs were analyzed. Comparing with semaglutide and liraglutide, tirzepatide exhibited fewer reported dsAEs while semaglutide and liraglutide showed a high correlation with non-lethal pancreatitis reports. Bupropion-naltrexone (31.65%) reported the highest number of dsAEs, and a PV signal was detected in mouth and lips AEs (ROR = 2.97, 95% CI: 2.42-3.6). Orlistat (ROR = 3.30, 95% CI: 3.08-3.55) exhibited the highest association with gastrointestinal AEs compared to other AOMs. PV signal for hepatobiliary AEs (ROR = 6.13, 95% CI: 3.45-10.88) with phentermine-topiramate still needs further clarification. Tirzepatide may be considered for patients with a history of digestive system disease or an elevated risk of pancreatitis based on the pattern of reported dsAEs. Caution is needed for the orofacial AEs when using bupropion-naltrexone. Orlistat has a higher reporting rate of gastrointestinal AEs, but these events are typically less severe. Phentermine-topiramate's association with liver impairment requires further clinical investigation. This article provides insights into the reported associations between AOMs and dsAEs, which may aid clinicians in making more informed decisions about individualizing medication and managing potential adverse events.
Sections du résumé
BACKGROUND
BACKGROUND
Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of these medications. However, most current studies are limited to the association of one class of drugs with specific digestive disorders, and there is no cascading analysis of AOMs in the digestive system. This study aims to use data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) for a stratified analysis of the reported associations between AOMs and dsAEs.
METHODS
METHODS
We analyzed adverse event reports submitted to FAERS between January 2015 and December 2023 related to obesity treatment. It is important to note that FAERS data cannot establish causality or incidence rates. Pharmacovigilance (PV) signals were detected by disproportionate analyses through proportionate reporting ratio (PRR), reporting odds ratios (ROR), and information components (IC) to detect dsAEs associated with AOMs. Reporting rates, severity, and response outcomes of digestive adverse events were compared across AOMs by multivariate logistic regression analysis.
RESULTS
RESULTS
Among 34,396 adverse events (AEs) related to obesity treatment, 8844 dsAEs were analyzed. Comparing with semaglutide and liraglutide, tirzepatide exhibited fewer reported dsAEs while semaglutide and liraglutide showed a high correlation with non-lethal pancreatitis reports. Bupropion-naltrexone (31.65%) reported the highest number of dsAEs, and a PV signal was detected in mouth and lips AEs (ROR = 2.97, 95% CI: 2.42-3.6). Orlistat (ROR = 3.30, 95% CI: 3.08-3.55) exhibited the highest association with gastrointestinal AEs compared to other AOMs. PV signal for hepatobiliary AEs (ROR = 6.13, 95% CI: 3.45-10.88) with phentermine-topiramate still needs further clarification.
CONCLUSIONS
CONCLUSIONS
Tirzepatide may be considered for patients with a history of digestive system disease or an elevated risk of pancreatitis based on the pattern of reported dsAEs. Caution is needed for the orofacial AEs when using bupropion-naltrexone. Orlistat has a higher reporting rate of gastrointestinal AEs, but these events are typically less severe. Phentermine-topiramate's association with liver impairment requires further clinical investigation. This article provides insights into the reported associations between AOMs and dsAEs, which may aid clinicians in making more informed decisions about individualizing medication and managing potential adverse events.
Identifiants
pubmed: 39267168
doi: 10.1186/s40360-024-00789-9
pii: 10.1186/s40360-024-00789-9
doi:
Substances chimiques
Anti-Obesity Agents
0
Liraglutide
839I73S42A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
64Informations de copyright
© 2024. The Author(s).
Références
Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight .
Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet (London England). 2017;390(10113):2627–42.
World obesity atlas. 2023. https://data.worldobesity.org/publications/?cat=19 .
Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Global Health. 2022;7(9).
Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254–66.
doi: 10.1056/NEJMra1514009
pubmed: 28099824
Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL. The global obesity pandemic: shaped by global drivers and local environments. Lancet (London England). 2011;378(9793):804–14.
doi: 10.1016/S0140-6736(11)60813-1
pubmed: 21872749
Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–98.
doi: 10.1038/s41574-019-0176-8
Ryan D, Heaner M. Guidelines (2013) for managing overweight and obesity in adults. Preface to the full report. Obes (Silver Spring Md). 2014;22(Suppl 2):S1–3.
National Clinical Guideline Centre. National Institute for Health and Care Excellence: guidelines. In: Obesity: identification, assessment and management of overweight and obesity in children, young people and adults: partial update of CG43. edn. London: National Institute for Health and Care Excellence (NICE), National Clinical Guideline Centre; 2014.
Frühbeck G, Toplak H, Woodward E, Halford JC, Yumuk V. Need for a paradigm shift in adult overweight and obesity management - an EASO position statement on a pressing public health, clinical and scientific challenge in Europe. Obes Facts. 2014;7(6):408–16.
doi: 10.1159/000370038
pubmed: 25503968
pmcid: 5644793
Tsai AG, Bessesen DH. Obesity. Ann Intern Med. 2019;170(5):Itc33–48.
doi: 10.7326/AITC201903050
pubmed: 30831593
Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, Yin X, Xu Q. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521.
doi: 10.3389/fendo.2023.1161521
Alsuhibani A, Thompson JR, Wigle PR, Guo JJ, Lin AC, Rao MB, Hincapie AL. Metabolic and bariatric surgery utilization trends in the United States: evidence from 2012 to 2021 national electronic medical records network %U. Annals Surg Open. 2023;4(4):e317. https://journals.lww.com/aosopen/fulltext/2023/12000/metabolic_and_bariatric_surgery_utilization_trends.28.aspx .
Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879–87.
doi: 10.1001/jama.2020.12567
pubmed: 32870301
Suissa K, Schneeweiss S, Kim DW, Patorno E. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States. Diabetes Obes Metab. 2021;23(7):1542–51.
doi: 10.1111/dom.14367
pubmed: 33651454
Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, Harindhanavudhi T, Sultan S, Singh S, Davitkov P. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198–225.
doi: 10.1053/j.gastro.2022.08.045
pubmed: 36273831
Nolen-Doerr E, Stockman MC, Rizo I. Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity. Curr Obes Rep. 2019;8(3):284–91.
doi: 10.1007/s13679-019-00350-4
pubmed: 31124035
Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs. 2006;66(12):1625–56.
doi: 10.2165/00003495-200666120-00012
pubmed: 16956313
Greig SL, Keating GM. Naltrexone ER/Bupropion ER: a review in obesity management. Drugs. 2015;75(11):1269–80.
doi: 10.1007/s40265-015-0427-5
pubmed: 26105116
Alfaris N, Minnick AM, Hopkins CM, Berkowitz RI, Wadden TA. Combination phentermine and topiramate extended release in the management of obesity. Expert Opin Pharmacother. 2015;16(8):1263–74.
doi: 10.1517/14656566.2015.1041505
pubmed: 25958964
Dekker TJA. Tirzepatide once Weekly for the treatment of obesity. N Engl J Med. 2022;387(15):1433.
doi: 10.1056/NEJMc2211120
pubmed: 36239652
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023;330(18):1795–7.
doi: 10.1001/jama.2023.19574
pubmed: 37796527
pmcid: 10557026
Iqbal J, Wu HX, Hu N, Zhou YH, Li L, Xiao F, Wang T, Jiang HL, Xu SN, Huang BL, et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev Official J Int Association Study Obes. 2022;23(6):e13435.
doi: 10.1111/obr.13435
Alsuhibani A, Alrasheed M, Gari M, Hincapie AL, Guo JJ. Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA adverse event reporting system (FAERS) databases 2013–2020. Int J Clin Pharm. 2022;44(1):172–9.
doi: 10.1007/s11096-021-01330-2
pubmed: 34564826
Weaver J, Willy M, Avigan M. Informatic tools and approaches in postmarketing pharmacovigilance used by FDA. AAPS J. 2008;10(1):35–41.
doi: 10.1208/s12248-007-9004-5
pubmed: 18446503
pmcid: 2751449
Zhou C, Peng S, Lin A, Jiang A, Peng Y, Gu T, Liu Z, Cheng Q, Zhang J, Luo P. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine. 2023;59:101967.
Takada M, Fujimoto M, Yamazaki K, Takamoto M, Hosomi K. Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database. Drug Saf. 2014;37(6):421–31.
doi: 10.1007/s40264-014-0163-x
pubmed: 24743876
Liu Y, Zhang HM, Jiang Y, Wen Z, Bao EH, Huang J, Wang CJ, Chen CX, Wang JH, Yang XS. Cardiovascular adverse events associated with new-generation androgen receptor pathway inhibitors (ARPI) for prostate Cancer: a disproportionality analysis based on the FDA adverse event reporting System (FAERS). Clin Genitourin Cancer. 2023;21(5):594–601e592.
doi: 10.1016/j.clgc.2023.07.003
pubmed: 37482524
Saladin KS, McFarland RK. Human anatomy. Volume 2. McGraw-Hill New York; 2008.
Park G, Jung H, Heo SJ, Jung I. Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance. Life (Basel Switzerland). 2020;10(8).
Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, et al. The REporting of a disproportionality analysis for DrUg Safety Signal Detection using individual Case Safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47(6):585–99.
doi: 10.1007/s40264-024-01423-7
pubmed: 38713347
pmcid: 11116264
Subeesh V, Maheswari E, Gr S, Swaroop AM, Minnikanti SS. A comparative study of Data Mining Algorithms used for Signal Detection in FDA AERS Database. J Young Pharmacists. 2018.
Khaleel MA, Khan AH, Ghadzi SMS, Adnan AS, Abdallah QM. A standardized dataset of a spontaneous adverse event reporting system. Healthc (Basel Switzerland). 2022;10(3).
Couzin-Frankel J. Obesity meets its match. Sci (New York NY). 2023;382(6676):1226–7.
doi: 10.1126/science.adn4691
Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials. Obes Rev Official J Int Assoc Study Obes. 2023;24(3):e13543.
doi: 10.1111/obr.13543
Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Cahen DL, van Raalte DH. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab. 2016;18(3):224–35.
doi: 10.1111/dom.12593
pubmed: 26500045
Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150–6.
doi: 10.1053/j.gastro.2011.02.018
pubmed: 21334333
Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London England). 2010;376(9741):595–605.
doi: 10.1016/S0140-6736(10)60888-4
pubmed: 20673995
Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obes (Silver Spring Md). 2013;21(5):935–43.
doi: 10.1002/oby.20309
Sternby B, Hartmann D, Borgström B, Nilsson A. Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine. Clin Nutr. 2002;21(5):395–402.
doi: 10.1054/clnu.2002.0565
pubmed: 12381337
Chen Y, Zhou J, Xu S, Liu M, Wang M, Ma Y, Zhao M, Wang Z, Guo Y, Zhao L. Association between the perturbation of bile acid homeostasis and valproic acid-induced hepatotoxicity. Biochem Pharmacol. 2019;170:113669.
doi: 10.1016/j.bcp.2019.113669
pubmed: 31628911
Phentermine-Topiramate. In. LiverTox: clinical and Research Information on Drug-Induced Liver Injury. edn. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
Perdomo CM, Cohen RV, Sumithran P, Clément K, Frühbeck G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet (London England). 2023;401(10382):1116–30.
doi: 10.1016/S0140-6736(22)02403-5
pubmed: 36774932
Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events Associated with Immune Checkpoint Blockade in patients with Cancer: a systematic review of Case Reports. PLoS ONE. 2016;11(7):e0160221.
doi: 10.1371/journal.pone.0160221
pubmed: 27472273
pmcid: 4966895